January 12, 2022 -- BostonGene Corporation and WellDyne have formed a strategic partnership to improve therapeutic decision-making for cancer patients. Using BostonGene's tumor portrait test, WellDyne will increase efficiency and therapy selection for patients who are candidates for immunotherapy in a variety of cancers.
The BostonGene tumor portrait test, based on integrated genomic and transcriptomic analysis, reveals key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
The test can significantly increase the correct identification of patients who respond to immunotherapy and may help other patients avoid unnecessary adverse events, the companies said. It combines precise data processing and proprietary algorithms to generate easy-to-understand tumor schematics, including BostonGene's molecular functional portrait, a personalized tumor map to guide treatment decision-making that tailors individualized treatments and streamlines treatment costs.
No financial details of the partnership were disclosed.
BostonGene Corporation is a biomedical software company that is committed to defining optimal, precision medicine-based therapies for cancer patients. WellDyne leverages precision medicine's targeted approach to predict how a patient will respond to specific drugs.